The enigmatic neutrophil: what we do not know

被引:0
作者
Paul Kubes
机构
[1] University of Calgary,Departments of Physiology and Pharmacology, Microbiology and Immunology and Critical Care Medicine, Snyder Institute for Chronic Disease
来源
Cell and Tissue Research | 2018年 / 371卷
关键词
Neutrophil killing mechanisms; Inflammation; Healing; Imaging; Neutrophil extracellular traps aggregates;
D O I
暂无
中图分类号
学科分类号
摘要
The neutrophil appears to be undergoing a renaissance of sorts. While it was for many years thought to be a killing machine brought into tissues to eradicate pathogens, it is now being implicated in many other processes, ranging from acute injury and repair, chronic inflammatory processes, cancer and auto-immunity. Not only is it an effector of the innate immune response, it appears to also potentially contribute to adaptive immunity, implicated in either contributing to the development of specific adaptive immune responses or perhaps even instructing and directing certain adaptive immune responses. With this renewed interest in the neutrophil and its numerous new functions, it is worth examining not what we know but rather what we do not know and what still needs to be more thoroughly examined. In this review, consideration is given to such topics as neutrophil subtypes, neutrophil differentiation, neutrophil as a director of immunity, neutrophil residency and ultimately death of the neutrophil.
引用
收藏
页码:399 / 406
页数:7
相关论文
共 50 条
  • [21] Chronic Heart Failure and Inflammation What Do We Really Know?
    Dick, Sarah A.
    Epelman, Slava
    [J]. CIRCULATION RESEARCH, 2016, 119 (01) : 159 - 176
  • [22] Perioperative Red Blood Cell Transfusion: What We Do Not Know
    Lei, Chong
    Xiong, Li-Ze
    [J]. CHINESE MEDICAL JOURNAL, 2015, 128 (17) : 2383 - 2386
  • [23] Neurocognitive decline in cardiac surgery patients: What do we know?
    Stanley, Madigan E.
    Sellke, Frank W.
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2023, 166 (02) : 543 - 552
  • [24] What Do We Know about Antimicrobial Activity of Astaxanthin and Fucoxanthin?
    Karpinski, Tomasz M.
    Ozarowski, Marcin
    Alam, Rahat
    Lochynska, Malgorzata
    Stasiewicz, Mark
    [J]. MARINE DRUGS, 2022, 20 (01)
  • [25] COVID-19, gender and estroprogestins, what do we know?
    Fidecicchi, Tiziana
    Fruzzetti, Franca
    Lete Lasa, Luis Ignacio
    Calaf, Joaquim
    [J]. EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2022, 27 (01) : 67 - 74
  • [26] Imaging Plaque Inflammation in Higher-Risk Patients: What Do We Know and What Are We Looking For?
    Ishai A.
    Tawakol A.
    [J]. Current Cardiovascular Risk Reports, 2015, 9 (6) : 1 - 8
  • [27] Enterotoxigenic Escherichia coli and probiotics in swine: what the bleep do we know?
    Dubreuil, Jean Daniel
    [J]. BIOSCIENCE OF MICROBIOTA FOOD AND HEALTH, 2017, 36 (03): : 75 - 90
  • [28] Burst Fractures in the Thoracolumbar Junction: What Do We Know About Their Treatment?
    da Silva, Otavio Turolo
    Joaquim, Andrei Fernandes
    [J]. ARCHIVES OF NEUROSCIENCE, 2016, 3 (04)
  • [29] Inflammatory pathways in the pathogenesis of iatrogenic laryngotracheal stenosis: what do we know?
    Davis, Ruth J.
    Hillel, Alexander T.
    [J]. TRANSLATIONAL CANCER RESEARCH, 2020, 9 (03) : 2108 - 2116
  • [30] Pirfenidone use in fibrotic diseases: What do we know so far?
    Torre, Aldo
    David Martinez-Sanchez, Froylan
    Mercedes Narvaez-Chavez, Sofia
    Ariel Herrera-Islas, Mariana
    Alberto Aguilar-Salinas, Carlos
    Cordova-Gallardo, Jacqueline
    [J]. IMMUNITY INFLAMMATION AND DISEASE, 2024, 12 (07)